Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 24696262)

1.

Clinical significance of serum tenascin-C levels in breast cancer.

Tastekin D, Tas F, Karabulut S, Duranyildiz D, Serilmez M, Guveli M, Vatansever S.

Tumour Biol. 2014 Jul;35(7):6619-25. doi: 10.1007/s13277-014-1875-3. Epub 2014 Apr 3.

PMID:
24696262
2.

Clinical significance of serum tenascin-c levels in epithelial ovarian cancer.

Didem T, Faruk T, Senem K, Derya D, Murat S, Murat G, Oznur K.

Tumour Biol. 2014 Jul;35(7):6777-82. doi: 10.1007/s13277-014-1923-z. Epub 2014 Apr 11.

PMID:
24722824
3.

Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients.

Degen M, Brellier F, Schenk S, Driscoll R, Zaman K, Stupp R, Tornillo L, Terracciano L, Chiquet-Ehrismann R, Rüegg C, Seelentag W.

Int J Cancer. 2008 Jun 1;122(11):2454-61. doi: 10.1002/ijc.23417.

PMID:
18306355
4.

The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer.

Karabulut S, Tas F, Tastekin D, Karabulut M, Yasasever CT, Ciftci R, Güveli M, Fayda M, Vatansever S, Serilmez M, Disci R, Aydıner A.

Tumour Biol. 2014 Sep;35(9):8849-60. doi: 10.1007/s13277-014-2151-2. Epub 2014 Jun 3.

PMID:
24891186
5.

c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.

Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, Paradiso A, Stea B, Zito A, Labriola A, Schittulli F.

Tumori. 2006 Jul-Aug;92(4):311-7.

PMID:
17036522
6.

Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients.

Shaker OG, Ay El-Deen MA, Abd El-Rahim MT, Talaat RM.

Tumori. 2006 Nov-Dec;92(6):524-30.

PMID:
17260494
7.

Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.

Papadopoulou E, Anagnostopoulos K, Tripsianis G, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A.

Neoplasma. 2008;55(3):229-38.

PMID:
18348656
8.

Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.

Samy N, Ragab HM, El Maksoud NA, Shaalan M.

Cancer Biomark. 2010;6(2):63-72. doi: 10.3233/CBM-2009-0119.

PMID:
20571232
9.

Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients.

Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras JL, Pichon MF.

Int J Biol Markers. 2004 Jan-Mar;19(1):14-22.

PMID:
15077922
10.

Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.

Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, Goh RY, Choi HJ, Park KJ, Roh MS, Kim HJ, Kwon HC, Lee JH.

BMC Cancer. 2010 May 14;10:203. doi: 10.1186/1471-2407-10-203.

11.

Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer.

Aharinejad S, Salama M, Paulus P, Zins K, Berger A, Singer CF.

Endocr Relat Cancer. 2013 Oct 14;20(6):777-83. doi: 10.1530/ERC-13-0198. Print 2013 Dec.

12.

Serum levels of transforming growth factor beta1 in patients with breast cancer.

Sheen-Chen SM, Chen HS, Sheen CW, Eng HL, Chen WJ.

Arch Surg. 2001 Aug;136(8):937-40.

PMID:
11485532
13.

Serum and urine survivin levels in breast cancer.

Guney N, Soydine HO, Derin D, Tas F, Camlica H, Duranyildiz D, Yasasever V, Topuz E.

Med Oncol. 2006;23(3):335-9.

PMID:
17018890
14.

Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis.

Decock J, Hendrickx W, Vanleeuw U, Van Belle V, Van Huffel S, Christiaens MR, Ye S, Paridaens R.

BMC Cancer. 2008 Mar 20;8:77. doi: 10.1186/1471-2407-8-77.

15.

The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy.

Hofmann G, Balic M, Dandachi N, Resel M, Schippinger W, Regitnig P, Samonigg H, Bauernhofer T.

Clin Biochem. 2013 Oct;46(15):1585-9. doi: 10.1016/j.clinbiochem.2013.06.010. Epub 2013 Jun 18.

PMID:
23792261
16.

Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients.

Ravishankaran P, Karunanithi R.

World J Surg Oncol. 2011 Feb 6;9:18. doi: 10.1186/1477-7819-9-18.

17.

High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.

Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J, Li L, Jia W, Zhang Y, Liu W, Wei W, Xie X.

J Cancer Res Clin Oncol. 2012 Feb;138(2):275-84. doi: 10.1007/s00432-011-1095-9. Epub 2011 Nov 25.

PMID:
22116318
18.

Urine tenascin‑C is an independent risk factor for bladder cancer patients.

Guan Z, Zeng J, Wang Z, Xie H, Lv C, Ma Z, Xu S, Wang X, He D, Li L.

Mol Med Rep. 2014 Mar;9(3):961-6. doi: 10.3892/mmr.2013.1873. Epub 2013 Dec 18.

PMID:
24366195
19.

Serum levels of hepatocyte growth factor in patients with breast cancer.

Sheen-Chen SM, Liu YW, Eng HL, Chou FF.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):715-7.

20.

Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis.

Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, Engle L, Chinchilli V, Costa L, Brady C, Seaman J, Lipton A.

Ann Oncol. 2004 Mar;15(3):455-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk